Latest Breaking News On - சிகிச்சை கண்டுபிடிப்பு - Page 3 : comparemela.com

Published: Jul 28, 2021   HOUSTON and CAMBRIDGE, Mass., July 28, 2021 /PRNewswire/  The University of Texas MD Anderson Cancer Center and Blueprint Medicines Corporation (NASDAQ: BPMC) today announced a three-year strategic research collaboration focused on accelerating development of BLU-222, an investigational precision therapy designed to target cyclin-dependent kinase 2 (CDK2). The collaboration brings together MD Anderson translational research scientists, the drug development capabilities of MD Anderson s Therapeutics Discovery division and Blueprint Medicines precision therapy pipeline and expertise. The teams seek to characterize the range of cancer types susceptible to treatment with a selective CDK2 inhibitor, advance BLU-222 mono- and combination-therapy strategies with the potential to maximize patient benefit, and identify novel biomarkers that may better predict treatment response and optimize patient selection.

United statesUnited kingdomTimothy heffernanFouad namouniBlueprint medicines corporationNational cancer instituteUniversity of texas md anderson cancer centerNational institutes of healthExchange commissionMd anderson translational research to advance therapeuticsCancer centerTherapeutics discoveryBlueprint medicineBlueprint medicinesTranslational researchAdvance therapeutics